OraSure Technologies, Inc. Form 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): September 9, 2003

 

 

OraSure Technologies, Inc.

(Exact name of issuer as specified in charter)

 

DELAWARE   001-16537   36-4370966

(State or Other Jurisdiction

of Incorporation or Organization)

   (Commission file number)  

(I.R.S. Employer

Identification Number)

 

220 East First Street

Bethlehem, Pennsylvania 18015-1360

(Address of principal executive offices)

 

(610) 882-1820

(Registrant’s telephone number, including area code)

 

 

Item 5 – Other Events and Regulation FD Disclosure.

 

OraSure Technologies, Inc. (the “Company”) issued a press release announcing the receipt of U.S. Food and Drug Administration approval of the Company’s OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples. The information contained in the press release dated September 9, 2003 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.

 

Item 7.   Financial Statements and Exhibits

 

(c) Exhibits

 

Exhibit Number
   

Description

99

    Press Release dated September 9, 2003, announcing receipt by OraSure Technologies, Inc. of U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples.

 

2

Signatures

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

       

ORASURE TECHNOLOGIES, INC.

Date: September 9, 2003       By:  

/s/ JACK E. JERRETT

               

Jack E. Jerrett

Senior Vice President, General Counsel and Secretary

 

 

Index to Exhibits

 

Exhibit Number
   

Description

99

    Press Release dated September 9, 2003, announcing receipt by OraSure Technologies, Inc. of receipt of U.S. Food and Drug Administration approval of its OraQuick® Rapid HIV-1 Antibody Test for use with venipuncture whole blood samples.